10x Genomics (TXG)
(Delayed Data from NSDQ)
$25.01 USD
-0.58 (-2.27%)
Updated May 17, 2024 04:00 PM ET
After-Market: $24.98 -0.03 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.01 USD
-0.58 (-2.27%)
Updated May 17, 2024 04:00 PM ET
After-Market: $24.98 -0.03 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
Earnings Preview: 10x Genomics (TXG) Q4 Earnings Expected to Decline
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 0.00% and 14.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Illumina-CDGN Partner to Create Coronavirus Tracking System
by Zacks Equity Research
Illumina (ILMN) partners with Australia's CDGN to track the national transmission of the virus causing COVID-19.
The Zacks Analyst Blog Highlights: 10x Genomics, Allscripts Healthcare and NextGen Healthcare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: 10x Genomics, Allscripts Healthcare and NextGen Healthcare
3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes
by Urmimala Biswas
Postponement of elective surgeries leading to lower product bookings cloud Zacks-Medical Info Systems industry prospects. However, coronavirus-led demand for contactless services should aid the space. TXG, MDRX, NXGN should be the forerunners.
10x Genomics (TXG) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
10x Genomics (TXG) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.